- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Topin & Associates for Dusa's ClindaReach
Pharmaceutical Executive
ClindaReach, from Dusa Pharmaceuticals, offers a simple and practical solution for patients with acne in hard-to-reach places: ClindaReach, an application wand.
REACH BACK
Topin & Associates
BRAND ClindaReach CLIENT Dusa Pharmaceuticals FROM LEFT: John Diaz, vice president, creative director; Michelle Rigot, copywriter
ClindaReach, from Dusa Pharmaceuticals, offers a simple and practical solution for patients with acne in hard-to-reach places: ClindaReach, an application wand.
Dermatologists are used to seeing ads featuring before-and-after photographs of smiling patients. But Dusa asked Topin to push the envelope. "The product is unique, so the client wanted to see something that was really different from other products and ads," says John Diaz, vice president, creative director.
Topin & Associates was charged with creating the launch campaign for the drug and demonstrating—in a simple iconic image—the benefit. But they also added a little humor with an interactive element. The creative produced by the agency first illustrated the hard-to-reach in an amusing way, and then let the audience reveal the ClindaReach solution by lifting a flap on the ad.
According to Diaz, the lighthearted depiction of the problem and visualization of the solution really connected with dermatologists, and created an extremely positive response.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
